Regentis Biomaterials Ltd. (RGNT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F/A for FY2025, filed Feb 27, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the RGNT SEC filings page.
This page shows Regentis Biomaterials Ltd. (RGNT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Regentis Biomaterials Ltd. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Regentis Biomaterials Ltd. reported a net loss of $13.6M while operations used $1.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Regentis Biomaterials Ltd. reported an operating loss of $7.0M against $79K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q4 2025.
Cash & Balance Sheet
Regentis Biomaterials Ltd. held $7.4M in cash as of Q4 2025; long-term debt is not reported for that period.
Not reported for Q4 2025.
Not reported for Q4 2025.
Margins & Returns
None of these metrics is reported for Q4 2025.
Capital Allocation
None of these metrics is reported for Q4 2025.
RGNT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
RGNT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2520-F/A | Q4'2420-F/A |
|---|---|---|
| Total Assets | $7.6M+1480.5% | $482K |
| Cash & Equivalents | $7.4M | N/A |
| Short-Term Investments | $0 | N/A |
| Long-Term Investments | $0 | N/A |
| Total Liabilities | $2.9M-93.1% | $41.6M |
| Current Liabilities | $2.9M-55.7% | $6.5M |
| Non-Current Liabilities | $0-100.0% | $35.1M |
| Total Equity | $4.7M+111.5% | -$41.1M |
| Retained Earnings | -$55.8M-32.4% | -$42.1M |
Not reported in any period shown, so not listed: Current Assets, Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
RGNT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
RGNT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Current Ratio, Asset Turnover, FCF Margin.
Where Regentis Biomaterials Ltd. Ranks
Frequently Asked Questions
Is Regentis Biomaterials Ltd. profitable?
No, Regentis Biomaterials Ltd. (RGNT) reported a net income of -$13.6M in fiscal year 2025.
What is Regentis Biomaterials Ltd.'s return on equity (ROE)?
Regentis Biomaterials Ltd. (RGNT) has a return on equity of -287.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Regentis Biomaterials Ltd.'s operating cash flow?
Regentis Biomaterials Ltd. (RGNT) recorded an outflow of $1.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Regentis Biomaterials Ltd.'s total assets?
Regentis Biomaterials Ltd. (RGNT) had $7.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What is Regentis Biomaterials Ltd.'s debt-to-equity ratio?
Regentis Biomaterials Ltd. (RGNT) had a debt-to-equity ratio of 0.61 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Regentis Biomaterials Ltd.'s return on assets (ROA)?
Regentis Biomaterials Ltd. (RGNT) had a return on assets of -179.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Regentis Biomaterials Ltd.'s P/E ratio?
Regentis Biomaterials Ltd. (RGNT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $12.7M as of Sep 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Regentis Biomaterials Ltd.'s price-to-sales ratio?
Regentis Biomaterials Ltd. (RGNT) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $12.7M as of Sep 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Regentis Biomaterials Ltd.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Regentis Biomaterials Ltd. (RGNT) held $7.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $1.4M over that year. Dividing the one by the other, the reported balance equals about 64 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Are Regentis Biomaterials Ltd.'s earnings high quality?
Regentis Biomaterials Ltd. (RGNT) reported a net loss of $13.6M while operations used $1.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Regentis Biomaterials Ltd. cover its interest payments?
Regentis Biomaterials Ltd. (RGNT) reported an operating loss of $7.0M against $79K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.